Tenax Therapeutics is projected to report a Q2 2026 net loss of $0.38 per share on zero revenue, with its stock currently trading at approximately $1.38 compared to a consensus analyst target of $20.62.
Investors are intensely focused on the company's next steps following the recent failure of its Phase 3 LEVEL trial for oral levosimendan, which missed its primary endpoint for exercise improvement. Despite the setback, management has emphasized positive signals in high-disease-burden subgroups and plans to engage the FDA to discuss a modified registrational path.
The company remains well-capitalized with $118 million in cash, providing an operational runway into the second quarter of 2028.